Zevra Therapeutics (ZVRA) announced that it has appointed Wendy Dixon, Ph.D., to the Company’s Board of Directors, effective immediately following the conclusion of the 2023 Annual Meeting of Stockholders, to fill the vacancy resulting from Dr. Travis Mickle’s resignation from the Board effective as of the day of the 2023 Annual Meeting to be held on April 25, 2023. Dr. Dixon is a seasoned biopharma executive with more than 40 years in senior leadership roles, including serving as Chief Marketing Officer and President of Global Marketing at Bristol Myers Squibb (BMY).
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZVRA:
- Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
- Zevra Therapeutics initiated with a Buy at Maxim
- Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative
- Zevra Therapeutics announces collaboration with RARE-X, Sleep Consortium
- Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders
